What is the recommended diagnosis and treatment approach for histoplasmosis in India?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diagnosis and Management of Histoplasmosis in India

For patients with suspected histoplasmosis in India, the recommended diagnostic approach is tissue biopsy with fungal stains (Grocott methenamine silver or periodic acid-Schiff) followed by treatment with liposomal amphotericin B for moderate-to-severe disease or itraconazole for mild disease. 1

Epidemiology in India

  • Histoplasmosis is an emerging endemic mycosis in India, with cases reported from various regions including Himachal Pradesh and Western India 2, 3
  • Often misdiagnosed as tuberculosis in India, leading to delayed treatment and potentially fatal outcomes 4
  • Both immunocompromised and immunocompetent individuals can be affected in India, though immunocompromised patients are at higher risk 2, 3

Clinical Presentation

  • Common manifestations include fever, fatigue, weight loss, hepatosplenomegaly, and lymphadenopathy 5
  • Respiratory symptoms (cough, chest pain, dyspnea) occur in approximately 50% of patients 5
  • Disseminated disease is common in immunocompromised patients, particularly those with HIV infection and CD4+ counts <150 cells/μL 1
  • Gastrointestinal involvement may present with diarrhea, abdominal pain, and gastrointestinal bleeding 6
  • CNS involvement can manifest as fever, headache, seizures, and mental status changes 5

Diagnostic Approach

  • Tissue biopsy with fungal stains (Grocott methenamine silver or periodic acid-Schiff) is the gold standard for diagnosis 1
  • Blood cultures have low sensitivity (~50%) but improved results with lysis-centrifugation method 1
  • Detection of Histoplasma antigen in urine or serum provides rapid diagnosis and is useful for monitoring treatment response 1
  • Conventional blood cultures may miss the diagnosis; specialized fungal cultures should be requested 1
  • Serological testing is most useful for chronic pulmonary histoplasmosis but may be less reliable in immunocompromised patients 1

Treatment Recommendations

Moderate-to-Severe Disease

  • Liposomal amphotericin B (3.0 mg/kg daily intravenously) for 1-2 weeks, followed by itraconazole (200 mg three times daily for 3 days, then 200 mg twice daily) for at least 12 months 1
  • Liposomal amphotericin B is preferred over amphotericin B deoxycholate due to higher response rates (88% vs. 64%) and lower mortality (2% vs. 13%) 1, 7
  • Alternative lipid formulations of amphotericin B at 5.0 mg/kg daily may be used if liposomal formulation is unavailable 1
  • Amphotericin B deoxycholate (0.7-1.0 mg/kg daily) can be used in patients at low risk for nephrotoxicity 1

Mild-to-Moderate Disease

  • Itraconazole (200 mg three times daily for 3 days, then 200 mg twice daily) for 6-12 weeks 1, 7
  • Blood levels of itraconazole should be monitored after at least 2 weeks of therapy to ensure adequate drug exposure 1, 7

Special Populations

  • For HIV-infected patients, antiretroviral therapy should not be withheld due to concerns about immune reconstitution inflammatory syndrome, which is rare and usually not severe 1
  • For patients with CNS histoplasmosis, liposomal amphotericin B (5.0 mg/kg daily for a total of 175 mg/kg over 4-6 weeks) followed by itraconazole for at least 1 year 1

Monitoring and Follow-up

  • Antigen levels should be measured during therapy and for 12 months after treatment completion to monitor for relapse 1
  • Hepatic enzyme levels should be measured before starting azole therapy and at 1,2, and 4 weeks, then every 3 months during treatment 7
  • Itraconazole blood levels should be monitored in cases of suspected treatment failure or concerns about absorption 7

Common Pitfalls in India

  • Misdiagnosis as tuberculosis is common due to similar clinical presentations 3, 4
  • Delayed diagnosis leads to increased mortality; maintain high clinical suspicion in endemic areas 3
  • Itraconazole capsules require high gastric acidity for absorption and should be taken with food 7
  • Patients receiving antacids, H2 blockers, or proton pump inhibitors should not use itraconazole capsules due to decreased absorption 7
  • Underreporting of histoplasmosis in India undermines its actual incidence and impact 4

Prophylaxis

  • Prophylaxis with itraconazole (200 mg daily) is recommended for HIV-infected patients with CD4+ counts <150 cells/μL in areas with high incidence of histoplasmosis (>10 cases per 100 patient-years) 1
  • May be appropriate for other immunosuppressed patients in specific circumstances 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Case Report: Histoplasmosis in Himachal Pradesh (India): An Emerging Endemic Focus.

The American journal of tropical medicine and hygiene, 2017

Research

Post kidney transplant histoplasmosis: An under-recognized diagnosis in India.

Transplant infectious disease : an official journal of the Transplantation Society, 2021

Guideline

Clinical Manifestations of Histoplasmosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Gastrointestinal Histoplasmosis: A Case Series.

International journal of surgical pathology, 2017

Guideline

Treatment of Histoplasmosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.